{
  "id": 1684626,
  "title": "Rocket Pharmaceuticals general counsel Wilson sells $11,809 in stock",
  "url": "https://urgent.news/2026/08/18/rocket-pharmaceuticals-general-counsel-wilson-sells-11-809-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-18T10:00:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/rocket-pharmaceuticals-general-counsel-wilson-sells-11809-in-stock-93CH-4864643"
  },
  "original_language": "en",
  "account": "Rocket Pharmaceuticals' General Counsel, Martin Wilson, sold 3,493 shares of the company's stock on August 13, 2026, for a total of approximately $11,809. The shares were sold at around the current market price of $3.40, which, according to InvestingPro analysis, appears to be undervalued based on its Fair Value calculation. Wilson made this transaction to cover tax withholding obligations for the vesting of Restricted Stock Units (RSUs), which convert into common stock on a one-to-one basis. After this sale, Wilson directly owns 674,484 shares of Rocket Pharmaceuticals, including the RSUs. Recently, Rocket Pharmaceuticals sold its Rare Pediatric Disease Priority Review Voucher for $180 million and held its 2026 Annual Meeting of Stockholders, where 74.02% of the outstanding common shares were represented. Shareholders approved the election of seven directors, and TD Cowen maintained a Hold rating on the company following a safety update on its RP-A501 gene therapy for Danon disease.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}